TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI Preparing RFA for Genetics Network; Patients Want Gene-Environment Studies August 9, 1996
TCL Archive ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies June 5, 2009
